2 options
Why is NOVO Nordisk charging Americans with diabetes and obesity outrageously high prices for Ozempic and Wegovy? : hearing before the Committee on Health, Education, Labor and Pensions, United States Senate, One Hundred Eighteenth Congress, second session, September 24, 2024.
Connect to full text Available online
View online- Format:
- Book
- Government document
- Author/Creator:
- United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions, author.
- Series:
- United States. Congress. Senate. S. hrg. ; 118-473.
- S. hrg. ; 118-473
- Language:
- English
- Subjects (All):
- Novo Nordisk.
- Weight loss preparations industry.
- Drugs--United States--Cost control.
- Drugs.
- Pharmaceutical industry--Government policy--United States.
- Pharmaceutical industry.
- Drugs--Prices--Health aspects--United States.
- Genre:
- Legislative hearings.
- Physical Description:
- 1 online resource (iii, 202 pages) : illustrations (some color), maps
- Place of Publication:
- Washington : U.S. Government Publishing Office, 2025.
- Participant:
- Hearing witnesses: Jergensen, Lars Fruergaard, President and Chief Executive Officer, Novo Nordisk, Bagsvaerd, Denmark.
- Notes:
- Access ID (govinfo): .
- In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).
- Includes bibliographical references.
- Date of hearing: 2024-09-24.
- Description based on online resource; title from PDF caption (GovInfo, viewed July 07, 2025).
- Other Format:
- Print version: United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Why is NOVO Nordisk charging Americans with diabetes and obesity outrageously high prices for Ozempic and Wegovy?
- OCLC:
- 1527059105
- Publisher Number:
- 57-255 (GPO jacket number)
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.